Key findings: Compared to matched controls: 12.8 higher odds of transfusion preterm birth (aOR ~1.8) No significant increase in reported PPH (recent cohort) Important nuance The lack of PPH signal doesnt mean no bleeding risk: Transfusion rates remain high Suggests bleeding + anemia (e.g., iron deficiency) may be underappreciated drivers What this tells us, even in modern care: VWD still impacts maternal outcomes Traditional endpoints (like PPH) may miss part of the picture Pre-delivery optimization (iron, hemostasis) matters as much as delivery management Clinical direction - Multidisciplinary care (Heme + MFM) - Routine iron deficiency screening - Better peripartum planning Ming Y Lim | G Bryce Christensen | George M
The role of semaphorin3A in myogenic regeneration and the formation of functional neuromuscular junctions on new fibres
At 1 mg/mL, you would need 12.5 units, easy to read and draw
For those new to GLP-1 treatments, starting with an easy-to-use format offering sustained effectiveness, like Orforglipron, is a preferable option
Treatment goals: Jardiance provides modest weight loss with added heart and kidney benefits, while Ozempic and Wegovy typically lead to more substantial long-term weight loss
